옵션 체인은 다양한 행사가격과 만기일에 대한 Cardinal Health의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Cardinal Health에 대한 시장 심리를 평가합니다..

Cardinal Health (NYSE:CAH) 주식, 옵션 체인

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

MSFT

CNN 머니 공포와 탐욕 지수(Fear &amp; Greed Index)가 전체 시장 심리가 하락했음을 보여주었고, 이 지수가 목요일에 &#34;공포&#34; 구역으로 이동했다. 미국 주식은 목요일에 하락세로 마감했으며, 나스닥 종합지수는 거래 중에 500포인트 이상 하락했다. S&amp;P 500과 나스닥 모두 9월 3일 이후 가장 큰 일일 하락폭을 기록했다.

메타와 MS의 급락으로 S&amp;P 500은 한 달 만에 최악의 세션 기록, 탐욕 지수가 &#39;공포&#39; 구간으로 이동

AAPL

AMZN

금요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 쉐브론(NYSE:CVX)은 월스트리트가 주당 2.43달러의 분기 순이익과 489억 9천만 달러의 매출을 예상하고 개장 전 실적을 발표할 예정이다. 쉐브론의 주식은 애프터마켓 거래에서 0.5% 하락하여 148.04달러로 거래되었다.

금요일 주목해야 할 주식: 애플, 아마존, 엑슨 모빌, 쉐브론 그리고 카디널 헬스

CSCO

OUST

SERV

수요일 미국 주식 선물은 혼조의 움직임을 보이며, 오늘 투자자들의 관심을 끌 가능성이 있는 주식은 다음과 같다: 월스트리트는 블링커 인터내셔널(NYSE:EAT)가 개장 전 매출 11억 6천만 달러, 주당 1.65달러의 분기 이익을 보고할 것으로 예상하고 있다. 브링커 주가는 시간외 거래에서 0.1% 하락한 70.35달러를 기록했다.

수요일 주목해야 할 주식: 블링커 인터내셔널, 시스코 그리고 3종목

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

UBS LUX MSC CANA ETF

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $119 to $127.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $127

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $119 to $124.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $124

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $134 to $139.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $139

Mizuho analyst Ann Hynes maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $110 to $120.

Mizuho Maintains Neutral on Cardinal Health, Raises Price Target to $120

Barclays analyst Stephanie Davis maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $117 to $133.

Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $133

Wall Street rebounded Friday following Thursday&#8217;s selloff, yet midday gains were still insufficient to prevent a second consecutive weekly decline for the S&amp;P 500, currently <a href="https://www.benzinga.com/markets">down 1% for the week. </a>
Concerns over tech earnings eased after Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) outperformed expectations, restoring some risk appetite and supporting the sector rebound.
Amazon shares surged over 6%, heading for their best session since February.
The Nasdaq 100, up by 1.1%, outperformed the S&amp;P 500, up 0.8%. 
In economic data, the U.S. economy added just 12,000 jobs in October, a steep drop from the 223,000 gain in September and well below the forecast of 113,000, as hurricanes and strikes led to hiring freezes nationwide. 
Despite the weak job figures, the unemployment rate held steady at 4.1%, indicating companies chose to retain workers rather than downsize.
The ISM Manufacturing PMI signaled contraction for the seventh consecutive month in October, with the index missing estimates.
Oil prices experienced a volatile session, initially spiking on reports of an imminent retaliatory attack by Iran on Israel before pulling back as those concerns faded. Gold edged down 0.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dipped 0.3%, slipping below the $70,000 mark.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,123.15</td>
<td>1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,161.88</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,751.05</td>
<td>0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,209.70</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.9% to $573.75.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.1% to $422.09.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.2% to $489.80.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.8% to $219.26.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 2%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), down 1.6%.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), up over 6%.</li>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), up 20%.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), down 0.7%.</li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), up 2.8%.</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), up 13%.</li>
<li>Dominon Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>), down 0.2%.</li>
<li>Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 6%.</li>
<li>CBOE Global Markets Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#NYSE">CBOE</a>), down 2.9%.</li>
<li>Waters Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), up 17%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690576/apple-q4-results-better-than-feared-analysts-highlight-iphone-16-demand-apple-intel">Apple Q4 Results &#8216;Better-Than-Feared&#8217;: Analysts Highlight iPhone 16 Demand, Apple Intelligence Opportunity After &#8216;Rock Solid Quarter&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

CBOE

CHTR

SPDR Dow Jones Industrial Average ETF Trust

INTC

TEAM

Select Sector SPDR-Consumer Discretionary

Tech Stocks Surge But S&P 500 Faces Second Weekly Decline, Amazon Rallies, Bitcoin Drops Below $70,000: What's Driving Markets Friday?

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Friday.
Shares of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) rose sharply during Friday's session as the company posted stronger-than-expected results for the <a href="https://www.benzinga.com/quote/AMZN">third quarter on Thursday</a>.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Amazon.com shares jumped 7.1% to $199.63 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) shares jumped 31.8% to $36.10 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 30% to $22.72 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) jumped 25.3% to $1.3145 after the company amended its services agreement with Apple to launch an extended MSS network with new satellites and infrastructure.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) gained 19.7% to $19.52.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) rose 17.3% to $378.98 after the company reported third-quarter earnings and sales that beat analyst estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 16.5% to $96.73 following third-quarter results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 15.8% to $218.37 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) rose 15.6% to $14.26 following better-than-expected quarterly earnings.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) gained 14.2% to $7.98. ASP Isotopes announced the pricing of public offering of common stock.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) surged 13.2% to $36.32 following better-than-expected quarterly earnings.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) gained 12% to $366.93 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) gained 11.5% to $89.49.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 9.9% to $55.56 after the company reported better-than-expected quarterly financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 9.6% to $14.92.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) surged 8.2% to $133.01 after the company raised its FY2024 adjusted EPS guidance.</li>
<li>Chart Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NASDAQ">GTLS</a>) gained 8.1% to $130.46 following quarterly results.</li>
<li>Dorman Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) gained 7.9% to $123.05 following upbeat earnings.</li>
<li>Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) jumped 7.8% to $42.54 following third-quarter results.</li>
<li>Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) gained 7.1% to $116.21 after the company reported better-than-expected first-quarter EPS and revenues and raised its FY2025 adjusted EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Intraday Update

Movers

ADMA

ASPI

DORM

GSAT

GTLS

HALO

LBRDA

MBLY

PRLB

TILE

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday

Cardinal Health Executive Says Company Will Actively Evaluate Additional Opportunities To Accelerate Growth In Specialty Therapeutic Areas; GLP-1 Drugs Are Continuing To Contribute To Revenue And "Grow More So Than We Had Originally Expected"

Friday,&nbsp;Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported first-quarter 2025 adjusted EPS of $1.88, up 9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.62</a>.
Sales decreased 4% to $52.28 billion, beating the&nbsp;consensus of $50.90 billion. Adjusted operating earnings increased 12% to&nbsp;$625 million.
First-quarter revenue for the Pharmaceutical and Specialty Solutions segment decreased by 5% to&nbsp;$48.0 billion. Excluding the customer contract expiration, revenue increased by 16%, driven by brand and specialty pharmaceutical sales growth <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679244/cardinal-health-reports-first-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook" rel="noreferrer noopener">from existing customers</a>.
Pharmaceutical and Specialty Solutions segment profit increased 16% to&nbsp;$530 million, driven by a higher contribution from brand and specialty products, including the earlier seasonal launch of COVID-19 vaccine distribution and positive generics program performance.
The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty drugs, and OTC products and offers services for specialty pharmaceuticals, supporting both manufacturers and healthcare providers and pharmacy management services.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40694838/opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurer" rel="noreferrer noopener">Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers</a>
Revenue for the Global Medical Products and Distribution segment increased 3% to&nbsp;$3.1 billion, driven by volume growth from existing customers.
Global Medical Products and Distribution (GMPD) segment profit decreased to&nbsp;$8 million, primarily due to higher manufacturing and health and welfare costs, largely offset by improved net inflationary impacts, including mitigation initiatives and growth from existing customers.
GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as distributes medical, surgical and laboratory products known as national brand products
&#8220;We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,&#8221; said&nbsp;Jason Hollar, CEO of Cardinal Health.
&#8220;The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year,&#8221; Hollar added.
Outlook:&nbsp;Cardinal Health has raised its fiscal year 2025 outlook for adjusted EPS to $7.75-$7.90 from <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b" rel="noreferrer noopener">prior guidance of</a> $7.55-$7.70 versus consensus of $7.63.
The guidance includes an update to the company&#8217;s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
The company also updated its Global Medical Products and Distribution segment profit outlook to&nbsp;$140 million&nbsp;to&nbsp;$175 million, from approximately&nbsp;$175 million, primarily due to the impact of higher health and welfare costs.
Additionally, the company updated expectations for its adjusted free cash flow to&nbsp;$1.0 billion&nbsp;to&nbsp;$1.5 billion, from approximately&nbsp;$1.0 billion.
Price Action: CAH stock is trading 2.97% higher at $111.74 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41661764/ford-to-halt-f-150-ev-production-for-7-weeks-next-month" target="_blank" rel="noreferrer noopener">Ford To Halt F-150 EV Production For 7 Weeks Next Month</a></li>
</ul>
Photo via Company

Guidance

Health Care

General

Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business

Investors on Wall Street could see some respite after major indices registered a downbeat session on Thursday. Index futures point to a positive start on Friday, ahead of the crucial monthly report on jobs data.
Thursday was a busy day as far as tech earnings are concerned, with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) reported their September quarter results.
While Meta and Microsoft both fell in after-market hours, Amazon surged after the company handily beat Street consensus. The company expects its fourth-quarter sales to surge between 7% to 11%.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.47%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.39%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.35%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.12%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.43% to $571.07 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) gained 0.51% to $486.33, according to<a href="https://benzinga.grsm.io/lxquj26b2sag"> Benzinga Pro data</a>.
Cues From Last Session:
All three major indices registered a downbeat Thursday, with S&amp;P 500 and Nasdaq Composite posting their biggest single-day fall since Sept. 3.
The overall investor sentiment declined, with the Greed index entering the "Fear" territory.
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, consumer discretionary, and real estate stocks recording the biggest losses on Thursday. However, utilities and energy stocks bucked the overall market trend, closing the session higher.
Crude oil prices edged up, mostly recovering their losses over the previous weekend due to Israel's missile strikes on Iran.
Treasury yields continued to climb amid fears of higher deficits due to a possible re-election of former President Donald Trump.
Besides, the International Monetary Fund has also warned about the long-term trajectory <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41495286/deficit-strain-in-washington-will-get-worse-imf-warns-national-debt-projections-rev">of U.S. national debt</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.76%</td>
<td>18,095.15</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.86%</td>
<td>5,705.45</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.90%</td>
<td>41,763.46</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.63%</td>
<td>2,196.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick, Chief Market Strategist at Carson Group, highlighted that November is the "best month of the year" as far as equity markets are concerned.
"The last time it fell more than 1% was in 2008, and it has been higher 11 of the past 12 years. Not to be outdone, it is the best month since 1950, in the past decade, and in election years, while it ranks as the second-best month the past 20 years (only July is better)."
Detrick <a href="https://www.carsongroup.com/insights/blog/seven-reasons-this-bull-market-is-alive-and-well/">added</a> that the bull market is here to stay. After experiencing a bull run for the past three years, the expert highlighted that "the potential for many more years of gains is actually quite high."
WisdomTree and Wharton School economist&nbsp;Jeremy Siegel, too, thinks earnings will beat interest rates, but there's something more important to consider.
He added that there could be increased anxiety in the markets until the election is over, after which there could be a bounce back.
However, Siegel added that he now anticipates only three 25-basis point rate cuts between now and June next year.
"Earnings will trump interest rates for stocks, but certainly for bonds, they are not good," Siegel told CNBC in <a href="https://www.cnbc.com/video/2024/10/31/earnings-will-trump-interest-rates-for-stocks-but-not-bonds-says-whartons-jeremy-seigel.html">an</a> interview.
On the economic data front, U.S. initial jobless claims declined by 12,000 from the previous week to 216,000 in the week ending Oct. 26.
The personal consumption expenditure price index rose 0.2% month-over-month in September following a 0.1% increase in August.
See Also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a>
Upcoming Economic Data:
<ul>
<li>The monthly jobs report is scheduled to be released at 8 a.m. ET.</li>
<li>S&amp;P&#8217;s final U.S. manufacturing PMI will be released at 9:30 a.m. ET.</li>
<li>Construction spending data will be released at 10 a.m. ET.</li>
<li>Auto sales data is expected to be released during the day.</li>
</ul>
Stocks In Focus:
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell 1.2% in premarket even as the company posted record quarterly revenue on the back of a rebound in iPhone sales.</li>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) will be on investors' radar after the company reported better-than-expected results during the September quarter. The stock is up 6.8% in premarket trading.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) is up nearly 6% in premarket trading even after the company posted a record loss of $16.6 billion during the September quarter.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares surged 1.3% in premarket trading after the company beat earnings per share (EPS) estimates, even though it posted a slight miss on revenue.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares continued to fall amid increased volatility, falling 3.3% in premarket trading. The stock fell 11.7% on Thursday.</li>
<li>Investors are awaiting earnings results from Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures gained in the early New York session, rising 2.08% as Iran prepares for another attack on Israel.
The benchmark 10-year Treasury note yield rose marginally to 4.289%.
Most Asian markets closed in the red on Friday, while European stocks were mostly higher in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41663633/biggest-gold-etf-posts-highest-monthly-inflows-in-2-5-years-as-investors-rush-to-">Biggest Gold ETF Posts Highest Monthly Inflows In 2.5 Years As Investors Rush To Safe Haven Ahead Of Presidential Election</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Federal Reserve

US Stocks Likely To Open Higher After 'Mag 7' Wrap Up Busy Week, Apple, Amazon And Intel On Radar: Investors Eye Monthly Jobs Report, Economist Says Earnings Won't Trump Bonds

WIIM

Cardinal Health shares are trading higher after the company reported better-than-expected Q1 EPS and revenues and raised its FY2025 adjusted EPS guidance.

<ul>
<li>This guidance includes an update to the company's Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.&nbsp;</li>
<li>The company also updated its Global Medical Products and Distribution segment profit outlook to $140 million to $175 million, from approximately $175 million, primarily due to the impact of higher health and welfare costs.&nbsp;</li>
<li>Additionally, the company updated expectations for its adjusted free cash flow to $1.0 billion to $1.5 billion, from approximately $1.0 billion.</li>
</ul>

Cardinal Health Raises Its Fiscal Year 2025 Outlook For Adjusted EPS To $7.75-$7.90 From Prior Guidance Of $7.55-$7.70 Versus Consensus Of $7.63

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported quarterly earnings of $1.88 per share which beat the analyst consensus estimate of $1.62 by 16.05 percent. This is a 9.3 percent increase over earnings of $1.72 per share from the same period last year. The company reported quarterly sales of $52.28 billion which beat the analyst consensus estimate of $50.90 billion by 2.72 percent. This is a 4.54 percent decrease over sales of $54.76 billion the same period last year.

Cardinal Health Q1 2025 Adj EPS $1.88 Beats $1.62 Estimate, Sales $52.28B Beat $50.90B Estimate

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the &#8220;Fear&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Nasdaq Composite falling more than 500 points during the session. The S&amp;P 500 and Nasdaq both recorded their biggest single-day declines since Sept. 3.
Shares of Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) fell around 4% on Thursday after the company reported third-quarter financial results. Shares of Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) fell around 6% on Thursday after the company reported first-quarter financial results.
On the economic data front, U.S. initial jobless claims declined by 12,000 from the previous week to 216,000 in the week ending Oct. 26. The personal consumption expenditure price index rose 0.2% month-over-month in September following a 0.1% increase in August.
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, consumer discretionary, and real estate stocks recording the biggest losses on Thursday. However, utilities and energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 378 points to 41,763.46 on Thursday. The S&amp;P 500 fell 1.86% to 5,705.45, while the Nasdaq Composite fell 2.76% at 18,095.15 during Thursday's session.
Investors are awaiting earnings results from Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), and Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 43.5, the index moved to the &#8220;Fear&#8221; zone on Thursday, versus a prior reading of 54.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

S&P 500 Records Worst Session In Over A Month, Meta And Microsoft Tumble: Greed Index Moves To 'Fear' Zone

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) to report quarterly earnings at $2.43 per share on revenue of $48.99 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Chevron shares fell 0.5% to $148.04 in after-hours trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported better-than-expected earnings and sales results for the fourth quarter. The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share. Apple shares fell 1.8% to $221.74 in the after-hours trading session.</li>
<li>Analysts are expecting Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) to post quarterly earnings at $1.88 per share on revenue of $93.94 billion. The company will release earnings before the markets open. Exxon Mobil shares fell 0.04% to $116.73 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) posted stronger-than-expected results for the third quarter on Thursday. Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year. Amazon shares jumped 6% to $197.50 in the after-hours trading session.</li>
<li>Analysts expect Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) to report quarterly earnings at $1.62 per share on revenue of $50.9 billion before the opening bell. Cardinal Health shares gained 0.1% to $108.65 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Apple, Amazon And 3 Stocks To Watch Heading Into Friday

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-01. Here's what investors need to know before the announcement.
Analysts estimate that Cardinal Health will report an earnings per share (EPS) of $1.62. 
The announcement from Cardinal Health is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.11, leading to a 1.46% increase in the share price on the subsequent day.
Here's a look at Cardinal Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.73</td>
<td>1.95</td>
<td>1.60</td>
<td>1.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.84</td>
<td>2.08</td>
<td>1.82</td>
<td>1.73</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730383271_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Cardinal Health were trading at $107.89 as of October 30. Over the last 52-week period, shares are up 8.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CAH/earnings">To track all earnings releases for Cardinal Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Cardinal Health

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $125 to $134.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $134

Cardinal Health Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is well-poised for growth, given its acquisition-driven strategy, a diversified product portfolio and a robust pharmaceutical segment. However, inflationary pressure remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 11.1% in the year-to-date period against the industry&#39;s 1.7% decline. The S&amp;P 500 Index has gained 20.6% in the same time frame.&nbsp;
CAH, with a market capitalization of $27.09 billion, is a nationwide drug distributor and service provider to pharmacies, healthcare providers and manufacturers. The company has an earnings yield of 6.8% compared with the industry&#39;s 5.3%. It anticipates earnings to improve 9.6% over the next five years.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ce/80495.jpg?v=1119199146" />
Image Source: Zacks Investment Research
<h2>What&#39;s Driving CAH&#39;s Performance?</h2>
Strength in Pharmaceutical Segment:&nbsp;Investors are upbeat about Cardinal Health&#39;s Medical and Pharmaceutical offerings, which provide the company with a competitive edge in the niche space.
The segment&#39;s products and services comprise pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services, which are expected to majorly drive the quarters ahead. For the past few quarters, the segment has been acting as a key catalyst when it comes to driving growth.
In the fourth quarter of fiscal 2024, pharmaceutical revenues amounted to $55.6 billion, up 13% on a year-over-year basis. The performance reflects branded pharmaceutical sales growth from Pharmaceutical Distribution and Specialty Solutions customers.
The company expects revenues from its Pharmaceutical segment to decline 4-6% year over year in fiscal 2025. The anticipated decline reflects a $39 billion revenue headwind due to the OptumRx contract expiration in June 2024. Segmental profit is likely to increase 1-3% from the previous guidance of at least 1%.
Long-term Supply Agreements:&nbsp;Cardinal Health is also pursuing growth via joint ventures and long-term supply agreements with several firms, which have likely kept the investors interested. The company entered into a long-term strategic agreement with Henry Schein. Under this deal, Henry Schein purchased Cardinal Health&#39;s medical supplies for physician practices. The collaboration is expected to drive core sales and prove accretive to CAH&#39;s earnings in the long term.
The signing of a 15-year agreement with Bayer Healthcare for the contract manufacturing of Xofigo is significantly positive. In our opinion, this should help CAH leverage its expertise in the nuclear pharmacy industry to expand access to a therapeutic agent and increase the use of radiopharmaceuticals in the United States and Canada.
Strong Q4 Results:&nbsp;Cardinal Health&#39;s impressive fourth-quarter fiscal 2024 results buoy optimism. The company&#39;s robust top-line results and solid performance in the Pharmaceutical segment were encouraging. Per management, the segmental performance was driven by brand and specialty pharmaceutical sales growth from existing customers.
Gross profit increased 5% year over year, driven by segmental growth.
<h2>Notable Developments</h2>
Last month, CAH announced an agreement to acquire Integrated Oncology Network (&quot;ION&quot;) for $1.115 billion in cash. ION will enhance CAH&#39;s oncology strategy, adding value for providers and patients. The partnership aims to equip community practices with advanced tools and technology, along with expertise from Specialty Networks&#39; PPS Analytics and SoNaR technology, enabling the company to deliver high-quality, patient-centered care close to home, ultimately improving patient outcomes and strengthening CAH&#39;s leadership in healthcare.
Cardinal Health signed a distribution agreement with Australia-based Telix to become the commercial radiopharmaceutical distributor to supply finished unit doses of Telix&#39;s PET agent, Zircaix, for the imaging of kidney cancer in the United States, subject to regulatory approval.
In August, Cardinal Health announced the opening of a new distribution center in Greenville, SC. The distribution center is dedicated to the company&#39;s at-Home Solutions business, which is also expected to add roughly 200 jobs to the region over time. The opening of the new distribution center is likely to provide a boost to CAH&#39;s at-Home Solutions business and generate additional revenues to support the growing market for at-home solutions.
<h2>What&#39;s Weighing on the Stock?</h2>
Cardinal Health faces the risk of losing considerable business in case of loss of a major customer, which, in turn, can severely impair its future revenues. In this regard, post the establishment of a generic sourcing joint venture with CVS Caremark in 2014, Cardinal Health largely depends on the former for more than 20% of its revenues.
Collectively, five of Cardinal Health&#39;s main customers, including CVS, accounted for as much as 40% of its revenues. Meanwhile, the company&#39;s pharmaceutical distribution contracts with OptumRx ended in June 2024. These represented 17% of total revenues in fiscal 2023. The non-renewal of the contracts is likely to adversely impact CAH&#39;s sales in fiscal 2025.
In July, the FDA issued a warning for Cardinal Health&#39;s Presource kit plastic syringe makers, Jiangsu Shenli Medical Production Co. Ltd and Jiangsu China, who have been facing FDA investigation. Recent inspections have unveiled multiple quality system violations, leading to warning letters and import alerts. CAH has recalled the affected products to ensure patient safety and compliance with the FDA regulations.
<div class="chart_embed">
<h3>Cardinal Health, Inc. Price</h3>
<img alt="Cardinal Health, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/e8/1728295731.png" style="height:251px; width:583px" title="" />
Cardinal Health, Inc. price | Cardinal Health, Inc. Quote
</div>
<h2>Estimate Trend</h2>
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $215.84 billion, indicating a 4.9% decline from the previous year&#39;s level.
The Zacks Consensus Estimate for adjusted earnings per share is pinned at $7.61, indicating a 1.1% increase from the year-ago reported numbers. The consensus estimate for adjusted EPS has improved 1 cent over the past 30 days.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;Baxter International&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>), each carrying a Zacks Rank #2 (Buy) at present.
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.58%.
Universal Health Service has gained 17.9% compared with the&nbsp;industry&#39;s&nbsp;19.8% growth in the past six months.
Quest Diagnostics has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics&#39; shares have risen 14.3% in the past six months compared with the&nbsp;industry&#39;s&nbsp;8% growth.
Baxter&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
BAX&#39;s shares have lost 17.9% in the past six months against the&nbsp;industry&#39;s&nbsp;5.8% growth.
<a href="https://www.zacks.com/stock/news/2346905/reasons-to-retain-cardinal-health-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346905">To read this article on Zacks.com click here.</a>

Earnings Beats

Offerings

Contracts

Management

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

Biotech

TTOO

T2 Biosystems Enters Multi-Year Exclusive U.S. Agreement With Cardinal Health To Sell FDA-Cleared Direct-From-Blood Diagnostics For Rapid Sepsis Detection, Including T2Dx Instrument, T2Bacteria Panel, And T2Candida Panel

Majorie Taylor Greene disclosed new stock transactions this week, which come as public efforts to ban members of Congress from trading continue to grow over <a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin">potential conflicts of interest.</a>
Here are the latest trades by the Republican House member from Georgia.
 What Happened: Greene has increased her frequency of trading disclosures <a href="https://www.benzinga.com/markets/equities/24/05/38611874/marjorie-taylor-greene-reveals-new-stock-trades-after-2-year-gap-berkshire-hathway-goldman-sachs">in recent months</a> with several large batches of stock purchases announced recently after a two-year hiatus of disclosures.
On Sept. 23, Greene disclosed her latest transactions, as reported by<a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene"> Benzinga's Government Trades page.</a>
Here are the stocks Greene bought, with each one disclosed as a value of $1,000 to $15,000:
<ul>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Berkshire Hathaway B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</li>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Southern Copper Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NASDAQ">SCCO</a>)</li>
<li>United Parcel Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
</ul>
Several of these purchases add to recent stakes taken by the representative, including shares of Berkshire Hathaway, Microsoft and CrowdStrike.
The disclosure by Greene did not report any sale transactions, which means the congresswoman continues to hold her Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares <a href="https://www.benzinga.com/general/social-media/24/08/40475137/djt-stock-hits-new-lows-since-trump-media-companys-public-debut-heres-how-much-marjorie-tayl">bought in October 2021.</a>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Greene disclosed buying Digital World Acquisition shares back in October 2021, the SPAC that took Donald Trump's media company public in March 2024.
The transaction was done with shares trading between $67.96 to $118.80. A tweet from UnusualWhales pins the purchase price at $94.20, meaning Greene is down significantly on her $15,000 to $50,000 purchase in the Trump-linked stock. Shares of DJT trade at $13.63 at the time of writing.
Greene buying CrowdStrike shares continues to be an area to watch as <a href="https://www.benzinga.com/general/politics/24/07/39585140/marjorie-taylor-greene-buys-cybersecurity-stock-owned-by-nancy-pelosi-why-trade-could-draw-red-f">Benzinga previously reported</a> the representative sits on the Subcommittee on Cybersecurity, Information Technology and Government Innovation, which operates under the House Committee on Oversight and Accountability.
With the latest stock transactions, Greene has increased her holdings in technology stocks along with placing bets on Warren Buffett to continue powering Berkshire Hathaway along after the stock hit a $1 trillion market capitalization.
Not many can say that their investing portfolios are betting on Donald Trump and Warren Buffett, but Greene can.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Government

Politics

CRWD

GOOG

LRCX

SCCO

Marjorie Taylor Greene Stays Loyal To Trump, Keeps DJT Stock, Buys Into Warren Buffett's Berkshire In Latest Trades

Cardinal Health, Inc. (CAH) Q1 2025 Earnings Call Transcript

Analyst Charles Rhyee of TD Cowen maintained a Hold rating on Cardinal Health (CAH – Research Report), boosting the price target to $130.00. Charle...

Balanced Outlook: Cardinal Health's Potential Growth Amid Conservative Forecasts and Temporary Challenges

Cardinal Health ( ($CAH) ) has released its Q1 earnings. Here is a breakdown of the information Cardinal Health presented to its investors. Cardina...

Cardinal Health Reports Strong Q1 FY2025 Results

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), Cardina...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vir Biotechnology (VIR), Cardinal Health (CAH) and Waters (WAT)

Barclays analyst Stephanie Davis raised the firm's price target on Cardinal Health (CAH) to $133 from $117 and keeps an Overweight rating on the sh...

Cardinal Health price target raised to $133 from $117 at Barclays

Evercore ISI analyst Elizabeth Anderson CFA initiated coverage with a Hold rating on Cardinal Health (CAH – Research Report) today and set a price ...

Cardinal Health (CAH) Gets a Hold from Evercore ISI

Morgan Stanley analyst Erin Wright raised the firm's price target on Cardinal Health (CAH) to $127 from $119 and keeps an Overweight rating on the ...

Cardinal Health price target raised to $127 from $119 at Morgan Stanley

Cardinal Health Q1 Earnings: Margins Signal More Upside

Leerink Partners analyst Michael Cherny has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday. Michael Cherny has given h...

Cardinal Health's Strong Start to FY2025: Buy Rating Affirmed Amid Robust Performance and Positive Outlook

Cardinal Health declares $0.5056 dividend

Press Releases

Cardinal Health expands medical product distribution footprint in Northeast Ohio

Cardinal Health celebrates Greenville, South Carolina, distribution center opening

Children's Hospital Association and Cardinal Health commemorate World Suicide Prevention Day with continued focus on youth mental health

Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®

Cardinal Health to acquire Integrated Oncology Network, a physician-led independent community oncology network

Cardinal Health to Announce First-Quarter Results for Fiscal Year 2025 on November 1

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

Comments

Cardinal Health

Cardinal Health (CAH) 옵션

Cardinal Health (NYSE:CAH) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌